Tag Archives: New England Journal of Medicine
By Pharm Exec | Published: August 4, 2014
Novartis reports that its KAE609 is the first antimalarial drug candidate with a novel mechanism of action to achieve positive clinical proof-of-concept in over 20 years.
By William Looney | Published: June 11, 2012
Multidrug resistant [MDR] TB is the front line in the global battle against infectious disease. It accounts for more than 5 per cent of new cases of TB, which itself takes more than 2 million lives per year – a death toll second only to HIV. More important, multidrug resistant TB is now found in […]